Skip to main content

Day: February 18, 2020

Rovio Entertainment Oyj: Omien osakkeiden hankinta 18.02.2020

Lisätietoja:Rene Lindell, talousjohtaja+358 207 888 300 (vaihde)RovioIR@rovio.comJakelu:Nasdaq Helsinki OyjKeskeiset tiedotusvälineetwww.rovio.comRovio lyhyesti:Rovio Entertainment Oyj on maailmanlaajuinen, peleihin keskittyvä viihdeyhtiö, joka luo, kehittää ja julkaisee mobiilipelejä, joita on jo tähän mennessä ladattu 4,5 miljardia kertaa. Rovio tunnetaan parhaiten Angry Birds -brändistään, joka sai alkunsa mobiilipelistä vuonna 2009 ja on sittemmin lisensointinsa kautta laajentunut peleistä erilaisiin viihde- ja kuluttajatuotekategorioihin. Tänään Rovio tarjoaa useita mobiilipelejä, animaatioita ja on tuottanut Angry Birds -elokuvan, joka oli ensi-iltaviikonloppunaan lipputulojen kärjessä 50 maassa, ja jonka jatko-osan, Angry Birds -elokuva 2 julkaistiin elokuussa 2019. Rovion pääkonttori on Espoossa ja yhtiö on listattu NASDAQ Helsingin...

Continue reading

Klépierre: DISCLOSURE OF TRADING IN OWN SHARES FROM FEBRUARY 10, 2020 TO FEBRUARY 17, 2020

RELEASEDISCLOSURE OF TRADING IN OWN SHARES FROM FEBRUARY 10, 2020 TO FEBRUARY 17, 2020Paris – February 18, 2020As announced in a press release dated February 06, 2019, Klépierre mandated an investment services provider to repurchase its own shares. The following table sums up the buyback transactions carried out by said provider between February 10 and February 17, 2020:

Continue reading

Klépierre: DÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉES DU 10 FÉVRIER AU 17 FÉVRIER 2020

COMMUNIQUÉDÉCLARATION DES TRANSACTIONS SUR ACTIONS PROPRES RÉALISÉESDU 10 FÉVRIER AU 17 FÉVRIER 2020Paris – 18 février 2020Dans le cadre de l’exécution de son programme de rachat d’actions annoncée par communiqué du 06 février 2019, le prestataire de service d’investissement mandaté par Klépierre a réalisé les transactions résumées dans le tableau qui suit entre le 10 février et le 17 février 2020 :

Continue reading

Eurobio Scientific : marquage CE du test Coronavirus de Seegene™

Eurobio Scientific : marquage CE du test Coronavirus de Seegene™Paris, le 18 février 2020 – 17h45Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce le marquage CE du panel ALLPLEX™ CORONAVIRUS, qu’Eurobio Scientific distribue exclusivement en France. Il s’agit du premier test de PCR* multiplexe en temps réel marqué CE IVD pour la détection des Coronavirus (sarbecovirus), et pour le typage du Covid-19, directement à partir du tube primaire.ALLPLEX™ CORONAVIRUS est un kit développé et fabriqué par le partenaire SEEGENE™ (Séoul, Corée du Sud), permettant la détection et la différentiation en un seul puits de PCR, des sarbecovirus ainsi que de 2 gènes d’identification du Covid-19. La technologie ALLPLEX™ donne l’opportunité de détecter simultanément...

Continue reading

Capgemini augments its data and analytics capabilities in Scandinavia with the acquisition of Advectas

Press Relations:Sam ConnattyTel.: +44 370 904 3601Email: sam.connatty@capgemini.comInvestor Relations:Vincent BiraudTel.: +33 1 47 54 50 87Email: vincent.biraud@capgemini.comCapgemini augments its data and analytics capabilities in Scandinavia with the acquisition of AdvectasStockholm, Paris, February 18, 2020 – Capgemini announced today the signing of an agreement to acquire Advectas, a leading business intelligence and data science company in Scandinavia. By joining Capgemini’s Insights & Data global business line, the 200+ strong Advectas team will help to further meet growing client demand for Capgemini’s business intelligence and data analytics services across the region.Founded in Sweden in 2006, to help companies make better business decisions based on data-driven insights, Advectas has a strong Scandinavian footprint with...

Continue reading

IBA – Transparency Notification

Louvain-la-Neuve, Belgium, February 18, 2020, 17.30Summary of the notificationIBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 17, 2020.In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and a disposal of equivalent financial instruments, its total holding in IBA SA remains the same as in its previous notification but its holding in voting rights has crossed upwards the 3% threshold on February 14, 2020.In details, on February 14, 2020, Norges Bank owned (A) 961.258 IBA shares with voting rights...

Continue reading

IBA – PUBLICATION RELATIVE À UNE NOTIFICATION DE TRANSPARENCE

Louvain-la-Neuve, Belgique, 18 Février 2020, 17.30Résumé de la notificationIBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l’article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), suite à une notification reçue le 17 février 2020.Dans sa notification, Norges Bank annonce que, suite à une acquisition d’actions IBA avec droit de vote et une cession d’instruments financiers assimilés, sa participation totale dans IBA SA est restée la même que lors de sa déclaration précédente mais que sa participation en actions avec droits de vote a franchi à la hause le seuil de 3% le 14 février 2020.En détail, au 14 février...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.